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Abstract
Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well 
established that EMP is a critical determinant of acquired resistance to cancer treatment modalities including 
radiation therapy, chemotherapy, and targeted therapies. Here, we aimed to explore how EMP contributes to 
cancer cell camouflage, allowing an ever-changing population of cancer cells to pass under the radar of our 
immune system and consequently compromise the effect of immune checkpoint blockade therapies. The ultimate 
clinical benefit of any combination regimen is evidenced by the sum of the drug-induced alterations observed in 
the variety of cellular populations composing the tumor immune microenvironment. The finely-tuned molecular 
crosstalk between cancer and immune cells remains to be fully elucidated, particularly for the spectrum of 
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malignant cells along the epithelial to mesenchymal axis. High-dimensional single cell analyses of specimens 
collected in ongoing clinical studies is becoming a key contributor to our understanding of these interactions. This 
review will explore to what extent targeting EMP in combination with immune checkpoint inhibition represents 
a promising therapeutic avenue within the overarching strategy to reactivate a halting cancer-immunity cycle 
and establish a robust host immune response against cancer cells. Therapeutic strategies currently in clinical 
development will be discussed.
Keywords: Epithelial-to-mesenchymal transition, epithelial-mesenchymal plasticity, immune evasion, tumor 
immune microenvironment, intrinsic and extrinsic mechanisms of resistance to immune checkpoint blockade, 
therapeutic opportunity
INTRODUCTION
The early history of cancer immunotherapy
The history of cancer immunology research dates all the way back to 1863 when Rudolf Virchow observed 
immune cell infiltration in tumors and hypothesized that sites of chronic inflammation served as a hot 
bed for cancer development[1,2]. Since then, numerous studies have explored the mechanistic link between 
chronic inflammation and cancer incidence, and tumor-promoting inflammation has been established as a 
hallmark of cancer[3-6]. However, in 1909, Paul Ehrlich postulated that the immune system could also have a 
protective role against tumorigenesis[7], and this concept was further developed and presented as the “theory 
of immunosurveillance” by Burnet and Thomas in the 1950’s[8-11]. Despite the fact that these early studies 
established a link between cancer and the immune system, the importance of the immune system in cancer 
progression and the therapeutic possibilities for cancer treatment remained largely neglected for nearly 
half a century. In fact, the theory of immunosurveillance was considered controversial until an important 
scientific discovery was published in Nature by Shankaran et al.[12] in 2001. The experimental evidence 
presented in this paper unambiguously showed that the immune system can, and often does, prevent 
tumors from developing, and that the immune status of mice is a critical determinant of their susceptibility 
to tumor development induced by chemical carcinogens[12,13].
A malignant cell may reveal its identity and alert the immune system in various ways. During malignant 
progression, cancer cells accumulate genetic mutations, which in turn may result in the expression of 
tumor-specific antigens, also known as neo-antigens. In addition, epigenetic alterations may also deregulate 
the expression of tumor-associated antigens such as cancer embryonic antigens or cancer testis antigens. 
Both tumor-specific and tumor-associated antigens can be recognized as foreign by the immune system 
and initiate immune cell-mediated clearing of the malignant cell population[14,15]. However, the strong 
selection pressure towards cancer cells that continuously expose tumor antigens and markers of cellular 
distress enforces a continuous interplay between cancer cells and immune cells, referred to as the process of 
“immunoediting”[9,13]. As a consequence of this constant selection pressure, malignant cells evolve to escape 
the immune system, and thus the concept of immunoediting could in part explain what was previously 
considered a controversy: the immune system may contribute to tumor suppression as well as tumor 
promotion[13].
Conceptually, the process of immunoediting consists of three sequential phases[9]. In the first phase, the 
innate and adaptive arms of the immune system work in concert to attack and eliminate the malignant cells 
(elimination phase). In the second phase, the adaptive arm of the immune system keeps the cancer under 
control by eliminating some cancer cells while others survive and proliferate, resulting in an equilibrium 
between dying and proliferating cells in the malignant tissue (equilibrium phase). In this phase, the cells 
that are still actively dividing will give rise to a population of more or less immunogenic cells, and clonal 
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expansion of less immunogenic cancer cells results in the third phase of the immunoediting process, 
wherein the tumor escapes from the immune response (escape phase). It is believed that malignancies can 
remain dormant and asymptomatic in the equilibrium phase of immunoediting for a prolonged period of 
time, in some cases even an entire lifetime, unless they can eventually “escape” the immune pressure and 
manifest as symptomatic and clinically detectable cancers. This notion is supported by autopsy studies 
that have revealed the prevalence of well-differentiated indolent malignancies or “pseudo cancers” of the 
thyroid, prostate and mammary glands[16]. The onset of the escape phase may be a result of alterations 
in the cancer cells themselves or through alterations in the tumor immune microenvironment (TIME), 
leading to an immunosuppressive state[9,13]. As all clinically detectable cancers have successfully escaped 
the immune response at least to some degree, the process of immunoediting represents a non-linear model 
where the evolution of the malignant cells and the TIME are mutually dependent on each other. The goal of 
cancer immunotherapy is to shift the equilibrium of cancer immunoediting from tumor tolerance towards 
eradication by modulating the crosstalk between malignant cells and the TIME.
The immune-oncology revolution
William Coley was the first to demonstrate that immune cells can kill cancer cells in patients. Already in 
1893, he treated cancer patients with a mixture of bacterial toxins (Coley’s toxins) in a successful attempt to 
activate the immune system to attack cancers[17,18]. Another approach to boost the immune system to fight 
cancer has been used for decades in the clinical management of early stage high-risk non-muscle-invasive 
bladder cancer, where Bacillus Calmette-Guerin, a vaccine originally intended for immunization against 
M. tuberculosis, is applied as an intravesical immunotherapy to induce a localized immune response[19,20]. 
However, immunotherapy did not emerge as a revolutionary cancer therapy for multiple cancer types until 
the recent development of immune checkpoint blockade (ICB) therapy. The concept of ICB is to utilize 
antibodies to block the receptor-ligand interactions of molecules that serve as negative regulators of the 
immune system, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell 
death protein 1 (PD-1). Work by Allison and colleagues showed that CTLA-4 functions as an immune 
checkpoint or “off-switch” by binding CD80/CD86 with greater affinity than the stimulatory “on-switch” 
CD28, thereby inhibiting activation and proliferation of T cells[21,22]. Ipilimumab (Yervoy®, Bristol-Myers 
Squibb, New York City, NY, US) is a humanized antibody that blocks CTLA-4, thereby reactivating the 
immune system. The clinical trials leading to US Food and Drug Administration (FDA) approval of 
ipilimumab in 2011 received enormous attention, as it was the first cancer treatment ever to demonstrate an 
increased overall survival in metastatic melanoma patients[23]. 
The interaction between the PD-1 receptor and its inhibitory ligand programmed death-ligand 1 (PD-L1) 
is another example of an inhibitory checkpoint modulating the duration and amplitude of the immune 
response against cancer cells[24-26]. Interactions between PD-1 and PD-L1 cause inhibition of T cell receptor 
(TCR)-mediated lymphocyte proliferation and cytokine secretion[26]. In a physiological context, PD-L1 
plays an important role in protecting host cells from immune-mediated tissue damage post-infection and 
preventing autoimmune disorders. PD-L1 is frequently overexpressed by malignant cells, allowing cancers 
to escape the adaptive immune system[27]. Numerous studies have reported that increased expression 
of PD-L1 in tumors is associated with poor prognosis[28-31]. Antibodies blocking the PD-1/PD-L1 axis 
have been shown to induce durable clinical responses in numerous cancer types including malignant 
melanoma[22,23,32], non-small cell lung cancer (NSCLC)[33,34], urothelial carcinoma[35,36], head and neck 
squamous cell carcinoma, Hodgkin’s lymphoma and renal cell carcinoma (RCC)[32-34,37-39]. This has led to 
FDA approval of several immune checkpoint inhibitors including the fully humanized monoclonal PD-
L1-targeting antibodies atezolizumab (Tecentriq®, Genentech/Roche, South San Francisco, CA, US) and 
durvalumab (Imfinzi®, AstraZeneca, Cambridge, UK), as well as monoclonal antibodies targeting PD-1; 
namely pembrolizumab (Keytruda®, Merck Sharp & Dohme, Kenilworth, New Jersey, US) and nivolumab 
(Opdivo®, Bristol-Myers Squibb, New York City, NY, US)[35,36,40,41].
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The remaining challenge
ICB truly represents a paradigm shift in cancer treatment[42]; not only do some patients experience 
profound clinical benefit from the treatment, but also it has been shown to induce durable responses for a 
subset of patients with aggressive malignancies[42,43]. Unfortunately, some of the most common cancers such 
as breast, prostate and colon cancer have shown poor responses to ICB[37,44]. Furthermore, even within the 
subtypes of cancers for which ICB therapy is indicated, heterogeneous responses have been shown, and a 
majority of the patients do not benefit from ICB therapy[42]. Furthermore, heterogeneous responses have 
been observed between multiple cancer lesions within the same patient[44]. The European Organisation 
for Research and Treatment of Cancer 18071 trial reported that more than half of high-risk patients with 
stage III melanoma who received adjuvant ipilimumab relapsed with a median recurrence-free survival of 
26.1 months[45]. The KEYNOTE-001 trial reported that one in four patients with metastatic melanoma who 
achieved an initial objective response to pembrolizumab subsequently experienced disease progression[45]. 
However, the reported outcomes of the efficacy of pembrolizumab treatment either alone or in combination 
with other treatments for advanced/metastatic melanoma varies considerably in the multiple studies 
performed, and a recent meta-analysis including 25 research articles with a total of 2,909 patients reported 
an overall response rate of only 34% (progression-free survival: 5.7 months, overall survival 20.3 months)[46].
Multiple mechanisms have been proposed to explain why only a subset of tumors respond to ICB, yet 
an urgent lack of reliable predictive biomarkers remains[37,42,47]. High cancer cell expression of immune 
checkpoint ligands, high tumor mutational burden (TMB) and a favorable immune cell infiltration in the 
TIME, i.e., immune cell inflamed “hot” as opposed to immune cell excluded “cold” tumors, have all been 
associated with a more favorable response to ICB[37,48,49]. The best predictive biomarkers identified so far 
include the TMB and neoantigen landscape of the tumor; however the adoption and harmonization of 
these methods in the clinic remain in their infancy[15,50,51]. For lack of better alternatives, PD-L1 expression 
is currently being used as a predictive biomarker for immune checkpoint inhibitors targeting the PD-1/PD-L1 
axis in malignant melanoma, NSCLC and RCC, but the usefulness of PD-L1 expression as a predictor of 
response to ICB remains a continuous matter of debate[42,52]. Thus, extensive efforts are currently being 
made to identify better predictive biomarkers and explore rational combinational therapies, with the 
ultimate aim to increase initial ICB response rates while also preventing or reversing the emergence of 
resistance[49,53]. 
In this review, we aim to explore how epithelial-mesenchymal plasticity (EMP), i.e., the acquired ability of 
epithelial cells to transition between epithelial and mesenchymal phenotypes, might contribute to cancer 
cell camouflage, enabling an ever-changing population of cancer cells to escape the immune system. 
Targeting EMP represents a promising therapeutic opportunity in combination with immune checkpoint 
inhibitors. Here, we aim to elucidate how EMP affects the various steps of the cancer-immunity cycle 
and to highlight some of the clinical evidence and molecular mechanisms supporting the hypothesis that 
targeting EMP represents a promising therapeutic avenue within the overarching strategy to reactivate a 
halting cancer-immunity cycle and establish a robust host immune response against cancer cells.
MAIN TEXT
Epithelial-mesenchymal transition and plasticity
The majority of human cancers are of epithelial origin[54]. As opposed to mesenchymal cells, which are 
characterized by their spindle-shaped fibroblast-like morphology and loose connection to surrounding 
cells, epithelial cells exhibit highly organized apicobasal polarity and junctional complexes ensuring 
stable intercellular adhesion and controlling transepithelial permeability. The process of epithelial-to-
mesenchymal transition (EMT) was first described in embryonic development[55-57], but was later associated 
with physiological and pathological processes occurring in adults such as wound healing, in the progression 
of carcinoma and indirectly in tissue fibrosis[58-63]. EMT is a cellular process where epithelial cells lose their 
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cell polarity and tight cell-cell adhesions, acquiring a fibroblast-like morphology and cytoarchitecture as 
well as the ability to remodel the extracellular matrix (ECM) and alter their cellular behavior to gain more 
migratory and invasive properties[55,62,64]. Considerable remodeling of the cytoskeleton accompanies the 
loss of epithelial cell polarity and confers new mechanobiological properties favoring migration and tissue 
invasion[62,63]. At the molecular level, EMT is characterized by downregulation of epithelial markers (e.g., 
E-cadherin and EpCAM), and upregulation of mesenchymal markers (e.g., N-cadherin and vimentin). 
Mesenchymal cells also exhibit increased expression of matrix metalloproteinases which are required for 
their invasive properties[65,66]. The most commonly recognized EMT transcription factors (TFs) include 
Snail (SNAI1), Slug (SNAI2), zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), and Twist 
family BHLH transcription factor 1[62,67]. Since multiple TFs may activate EMT, different combinations of 
TFs may be responsible, at least in part, for the heterogeneity that stems from different versions of the EMT 
program[60]. Of note, the EMT International Association suggests that EMT should not be assessed solely 
on the basis of EMT-TF expression or that of a small number of molecular markers, but rather the primary 
criteria for defining EMT should consist of measurable alterations in cellular characteristics together with a 
set of molecular markers[62]. 
Importantly, EMT is not an irreversible linear process, and the reverse process, mesenchymal-to-epithelial 
transition (MET), describes the transition from the mesenchymal (M) to the epithelial (E) state[68]. 
Although EMT was initially believed to be a binary process, it is now well documented that this is indeed a 
dynamic process and intermediate-state cells also exist[61,69]. Cells can thus undergo partial EMT or partial 
MET to obtain intermediate E/M states with a cellular phenotype that is neither completely epithelial nor 
completely mesenchymal and harbors attributes characteristic of both states[62,69]. Rather than acting as 
an “on/off” switch between the E and M states, the process of EMT is therefore considered to generate a 
continuum of cell states along an “epithelial-mesenchymal axis”, also frequently referred to as an “EMT 
scale” or “EMT spectrum”[60,70]. Tan and colleagues have developed a universal and quantitative gene 
expression-based EMT scoring system used to establish and evaluate an EMT spectrum across different 
cancer types[69]. Recently, the term “epithelial-mesenchymal plasticity” (EMP) has been increasingly 
recognized, referring to the ability of cells to adopt mixed E/M features and to switch between various 
states along the epithelial-mesenchymal spectrum[62]. Although carcinoma cells may hijack this conserved 
developmental program, its physiological role in maintaining homeostasis is highly regulated both spatially 
and temporally, while the pathological EMT program detected in cancers, on the other hand, appears to be 
a mainly stochastic and time-independent process[65,66,71]. Of note, non-epithelial cancers such as melanoma 
have also been shown to undergo EMT-like programs leading to similar phenotypic changes induced 
by EMT-related genes, and serve as a model system for studying metastasis and therapy resistance[72-74]. 
Phenotypic switching in melanoma involves re-organization of the cytoskeleton, cell membrane and cellular 
adhesions, as well as alterations in common EMP-related phenotypic markers including gain of E-cadherin 
and loss of N-cadherin expression[72]. 
Under pathological conditions, epithelial cells are believed to undergo EMT, but they rarely or perhaps 
never undergo the full EMT transition to obtain a completely mesenchymal phenotype, suggesting 
that partial EMT represents the norm rather than the exception[60,62]. Evidence also indicates that these 
intermediate E/M phenotypes have the greatest malignant and metastatic potential[75-77]. Carcinoma cells 
can also temporarily transition to a more plastic state to metastasize or overcome selection pressures from 
therapy and subsequently revert to an epithelial-like state[75]. Expression of EMT-TFs is also frequently 
accompanied by features of stemness. Retention of stemness has been linked to EMT and in particular to a 
stemness window around intermediate E/M states[61]. Like EMP, the acquisition of stem cell traits in cancer 
cells is not considered a fixed trait; rather it represents a hallmark of cancer within a spatial and temporal 
window in cancer progression[61]. Accumulating evidence suggests that morphological phenotype and 
stemness can be regulated independently in malignant cells, but that a stemness window along the EMT 
axis may predispose malignant cells for acquisition of stem cell traits[61].
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EMP as a mediator of resistance to cancer therapies 
Even for the most effective cancer therapies, be it chemotherapy, targeted therapies, radiotherapy or 
immunotherapy, persisting cancer cells that survive treatment are believed to constitute a reservoir of slow-
cycling cells that eventually may acquire irreversible genetic mutations or epigenetic alterations causing 
therapy resistance and relapse[78-80]. Acquired therapy resistance is one of the major obstacles to achieving 
durable remission, and thus major efforts have been made to understand the mechanisms of drug resistance 
against targeted therapies as well as more conventional cancer treatment regimens. Historically, the focus 
of this research has been to uncover genetic mutations responsible for acquired drug resistance, such as 
secondary mutations in the target gene, causing impaired drug binding, or mutations causing activation 
of downstream signaling or alternative survival pathways[78,81]. However, recent attempts to characterize 
resistance mechanisms to targeted therapies, such as that of third-generation anaplastic lymphoma kinase 
(ALK) inhibitor loratinib resistance by next-generation sequencing and phenotypic analysis of longitudinal 
tumor samples, have highlighted EMT as a mediator of resistance in cases where a specific mutation 
affecting drug binding could not be detected[82]. Furthermore, the EMT-mediated loratinib resistance found 
in these patient-derived cell lines could be overcome by combined SRC and ALK inhibition[82]. EMP has 
been shown to be widely associated with therapy resistance against both cytotoxic and targeted therapy in 
multiple cancer types, and increasing evidence also shows that EMP contributes to a multidrug resistance 
phenotype[58,60,71,83]. However, the exact mechanism by which EMP contributes to drug resistance in these 
various contexts remains to be fully elucidated. Proposed mechanisms include reduced levels of pro-
apoptotic proteins or increased drug efflux, which may be part of a broader association between EMT-
mediated cancer cell dedifferentiation, acquisition of stem cell traits, and drug resistance[78,83-87]. Although it 
has been acknowledged for quite some time that dynamic chromatin modifications may be an independent 
route to drug resistance in cancer cells and thus embodies a promising drug target in combination with 
various drugs including ICB, it was not until the recent FDA approval of tazemetostat (Trade name: 
Tazverik, developer: Epizyme), a first-in-class small molecule inhibitor of enhancer of zeste homolog 2 
(EZH2), that this hypothesis has been feasible for clinical testing. Tazemetostat was FDA approved as a 
monotherapy in January 2020 for patients with histologically confirmed, metastatic or locally advanced 
epithelioid sarcoma with INI1 loss, and was thus the first “epigenetic” drug approved for solid cancers. 
EZH2 is considered a master regulator of EMT through orchestrating the regulation of the H3K27me3 
epigenetic mark, and in pancreatic cancer it has been shown to regulate EMT through miRNA 139-5p. 
Tazemetostat is currently in phase 2 clinical trials in combination with the PD-1 inhibitor TecentriqTM 
(atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and thus 
future combination studies will need to address whether EZH2 inhibitors or other epigenetic drugs can 
reduce EMT and increase response to ICB in pancreatic cancer or other solid cancers. 
Novel technologies leveraging single cell analysis have only just begun to provide a better mechanistic 
understanding of the processes at play. In several recent studies in vitro, drug-tolerant persister cells, 
sometimes referred to as “jackpot” cells, have been observed in cancer cell cultures from a variety of tumor 
types upon treatment[78,80,88-91]. From single-cell sequencing endeavors, these studies have shown that many 
cancers, including melanoma, display a profound transcriptional variety at the single cell level. Through 
single-cell gene expression analyses of melanoma cultures, Shaffer and colleagues were able to demonstrate 
that non-heritable resistance to the V600E mutated BRAF inhibitor vemurafenib (Zelboraf, Plexxikon and 
Genentech) was established from a very rare (1 per 50-500 cells) subpopulation of pre-existing pre-resistant 
cells. These cells transiently express a semi-coordinated set of well-known plasticity and resistance markers, 
including epidermal growth factor receptor (EGFR), platelet derived growth factor receptor beta, nerve 
growth factor receptor, fibroblast growth factor receptor 1, Wnt family member 5A (WNT5A), JUN and 
the receptor tyrosine kinase AXL[91]. Treatment with vemurafenib induced a stepwise reprogramming of the 
pre-resistant cells into a stable resistant phenotype, which was not affected by drug holidays[91].
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AXL expression in melanoma has been associated with resistance mechanisms mediated by mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling[92-94]. Tirosh and 
colleagues provided strong evidence for the involvement of AXL as well as AXL-related genes (AXL 
signature) in acquired melanoma resistance to both vemurafenib and the MEK inhibitor trametinib 
(Mekinist, Novartis, Basel, Switzerland), and also found that the proportion of a similar population 
of “jackpot” cells as well as the abundance of plasticity gene transcripts significantly increased after 
resistance was acquired in vitro, while being selected against more differentiated populations expressing 
melanocyte-inducing transcription factor (MITF) and SRY-box transcription factor 10[95]. Taken together, 
the accumulating evidence for the role of rare “jackpot” cells in acquired therapy resistance supports the 
hypothesis that intervention with cytotoxic or targeted therapies and immunotherapies displaying initial 
efficacy in tumor eradication may also act as selection pressures, predisposing tumors to immune evasion 
through the acquisition of plasticity phenotypes and priming cells for immune resistance. The adoption of 
distinct phenotypes through the process of EMT may provide cells with properties adaptive to changes in 
the TIME, and thus act as drivers towards a phenotypic state independent of the drug-targeted pathways[78]. 
The tumor immune microenvironment as a regulator of epithelial-mesenchymal plasticity 
The tumor microenvironment is a key regulator of EMP, which may be induced by combinations of 
multiple microenvironmental factors including hypoxia, pH, ECM composition, tensile forces and the 
presence of soluble factors such as interferons, inflammatory cytokines and growth factors[61,65,66,86,96-98]. 
Hypoxia occurs in most actively growing solid tumors and is an important EMT inducer. Accumulating 
evidence also suggests that hypoxic stress is linked to therapy resistance as well as regulation of tumor 
immunogenicity and both tumor and immune plasticity[99,100]. Hypoxic areas of growing tumors have been 
shown to attract immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), tumor-
associated macrophages (TAMs) and regulatory T cells (Tregs)[101], and hypoxia has also been shown to 
upregulate PD-L1 on MDSCs[102,103]. Targeting hypoxia has thus been suggested to improve the efficacy 
of cancer immunotherapy[102,104,105]. Remodeling of ECM through secretion of specific matrix MMPs 
and new ECM components, namely collagen type 1, has been shown to induce EMT through both 
mechanotransduction and direct membrane receptor signaling through integrins and DDR1/2[106-108]. 
Cancer-associated fibroblasts (CAFs), in addition to their role in ECM remodeling, serve as one of the 
primary sources of key EMT-inducing growth factors including hepatocyte growth factor (HGF), fibroblast 
growth factor, interleukin (IL)-6 and transforming growth factor-beta (TGF-β); however, molecular 
profiling and ablation of heterogeneous CAF subsets in various tumor models have shown conflicting 
and context-dependent effects on the efficacy of different therapies[109]. Thus, for CAFs and other cellular 
components of the TIME, the continuum of cells along the differentiation/polarization axis is far more 
complex than previously anticipated and remains to be explored further by high-dimensional analyses. 
Multiple studies have demonstrated that the TIME strongly contributes to the induction of the EMT 
program and subsequent tumor progression[66]. Cells of the TIME that are involved in regulating EMP 
include TAMs, MDSCs, neutrophils and natural killer (NK) cells[110,111]. TAMs have a major role in 
orchestrating cancer-related inflammation, and pro-inflammatory macrophages have been shown to 
induce EMT at the invasive margin of the tumor through inflammatory cytokine tumor necrosis factor-α 
(TNF-α)-mediated stabilization of the transcription factor SNAI1 via nuclear factor-κB (NF-κB) pathway 
activation, while knockdown of SNAI1 suppressed inflammation-mediated breast cancer metastasis, 
suggesting a mechanism for EMT as a regulator of inflammation-induced metastasis[112]. Macrophages 
have also been shown to induce EMT in intratumoral cancer cells via TGF-β secretion and activation of 
the β-catenin pathway[113]. In a murine melanoma model, MDSCs were shown to infiltrate the tumor and 
induce EMT in vivo[114]. Functional in vitro assays with purified MDSCs revealed that the TGF-β, epidermal 
growth factor (EGF) and HGF signaling pathways were all involved in MDSC-induced EMT activation of 
cancer cells[114]. In a similar model, HGF secretion by T cell-inflamed TIMEs was shown to mobilize and 
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recruit neutrophils through binding and activation of c-MET, wherein they gained immunosuppressive 
properties[115]. Neutrophils are also frequently enriched at the invasive margin of gastric cancers, and in a 
recent study, tumor-associated neutrophils were shown by in vitro co-culture experiments to promote EMT 
in gastric cancer cells via IL-17α signaling[116]. Although the mechanisms are still unclear, NK cells may 
increase the malignancy of melanoma cells by inducing an EMT-like switch[110].
The role of EMP in the cancer-immunity cycle
The finely tuned, step-wise process by which the immune system can efficiently recognize and eradicate 
cancer cells was first conceptualized by Chen and Mellman and is now widely known as “the cancer-
immunity cycle”[117]. In the first step of the cancer-immunity cycle, cancer antigens are recognized and 
captured by professional antigen-presenting cells (APCs), such as dendritic cells (DCs)[117]. Alarmins or 
damage-associated molecular patterns (DAMPs) released by dying tumor cells may aid in the attraction 
of APCs to the tumor bed[118,119]. This initiation of the cancer-immunity cycle is dependent on the APCs 
capturing both cancer specific antigens expressed by the cancer cells (immunogenicity) as well as signals 
that specifically evoke an immune response (adjuvanticity)[117,120]. Toll-like receptors (TLRs) are expressed 
on DCs and are key mediators bridging innate and adaptive immunity once stimulated by foreign 
pathogen associated molecular patterns (PAMPs) or DAMPs. TLR activation results in the secretion of 
pro-inflammatory cytokines including IL-6, IL-12, TNF-α, and type I interferons, which in turn serve to 
recruit immune effector cells. The APCs from step one of the cancer-immunity cycle travel from the tumor 
microenvironment to the lymph node where they present captured cancer related antigens to T cells (step 2). 
T cells can then be activated and programmed to specifically react to these antigens (step 3). Activated 
cytotoxic T lymphocytes (CTLs) then travel back to the tumor site (step 4) where they are then able to 
infiltrate the tumor (step 5), recognize (step 6) and kill (step 7) the antigen-presenting cancer cells[117]. All 
these steps need to be intact for the cancer-immunity cycle to be successfully completed.
As discussed below, EMT may affect several steps of the cancer-immunity cycle and thus hinder 
progression in this finely-tuned cycle in multiple ways [Figure 1]. One of the remaining challenges will be 
to identify the “Achilles heel” of individual cancer cases and tailor the treatment to initiate a robust cancer-
immunity cycle. We suggest that targeting cancer EMP may represent a unique opportunity to bolster 
several steps of the cancer-immunity cycle. Although the molecular mechanisms of EMP affecting the 
various steps of the cancer-immunity cycle are still largely obscure, targeting EMP represents a promising 
therapeutic addition within the overarching strategy of personalized cancer immunotherapy to re-activate a 
halting cancer-immunity cycle and re-establish a robust host immune response against the cancer cells[53,121].
Using hypoxia-inducible factor 1-alpha (HIF1 alpha) and AXL inhibitors as examples, the rationale 
behind clinical trials combining ICB and mediators of epithelial phenotypic plasticity are based on the 
effects of these drugs on multiple steps of the cycle. First, cancer treatments that induce immunogenic 
cell death (ICD) have been shown to contribute to anticancer immune attack, mediated by the exposure 
of DAMPs. Hypoxia is a strong microenvironmental factor that supports coordinated induction of EMT 
and also AXL expression and autophagy. The HIF1 alpha inhibitor PX-478 was also recently shown to 
enhance gemcitabine-induced immune responses and eliminate pancreatic ductal adenocarcinoma (PDAC) 
cells through induction of ICD[122]. EMT correlates with autophagy induction, and pre-mortem stress-
related autophagy is also linked to the release of DAMPs and induction of ICD[53,123]. Thus, the impact 
of targeting autophagy to increase the efficacy of immune checkpoint inhibition is expected to be seen 
particularly in cancers of an immune cold or immune-excluded immunophenotype[49]. We have recently 
shown that the small molecule AXL inhibitor bemcentinib abrogates the autophagic flux and is a potent 
inducer of ICD; this is of particular interest as it implicates a favorable adjuvant effect and alteration of 
the TIME upon AXL inhibition in immunogenic but immunosuppressed tumors[53,124]. In this context, 
it is important to note that the increased danger signaling per se is not sufficient to compensate for the 
Lotsberg et al . Cancer Drug Resist  2020;3:[Online First]  I  http://dx.doi.org/10.20517/cdr.2020.41                                   Page 9
Figure 1. EMP affects various steps of the cancer-immunity cycle. The therapeutic rationale for targeting EMP in combination with ICB 
is based on the fact that EMP affects multiple steps of the cancer-immunity cycle described by Chen and Mellman[117]. Briefly, targeting 
EMP can induce an increased release of DAMPs serving as an adjuvant during the release of cancer cell antigens (STEP 1). DAMPs 
are further recognized by pattern recognition receptors (PRRs) including TLRs. EMP targeting can induce an M1 to M2 polarization of 
macrophages and an activation of APCs, and thus aid in cancer antigen presentation (STEP 2). Targeting EMP and the EMP-associated 
immunosuppressive tumor immune microenvironment (TIME) can enable the infiltration of educated T cells into the cancer (STEP 5). 
EMP is associated with reduced recognition (STEP 6) and immune effector cell-mediated killing (STEP 7) of cancer cells, and targeting 
EMP can therefore induce increased effector cell-mediated lysis of cancer cells and propagation of the cycle. Adapted courtesy of Chen 
and Mellman[117]. EMP: epithelial-mesenchymal plasticity; ICB: immune checkpoint blockade; DAMPs: damage-associated molecular 
patterns; APCs: antigen-presenting cells 
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intrinsically low immunogenicity of some tumors, and that the effect of autophagy-dependent danger 
signaling is solely expected to warm up immune cold tumors and elicit a strong immune response in 
immunogenic tumors[125]. Increased immunoadjuvanticity, that is, the recruitment of professional APCs 
to educate the naïve T lymphocyte population, is critical to maximize the potential therapeutic benefit 
of ICB. Furthermore, AXL has been shown to suppress antigen presentation by downregulating major 
histocompatibility complex I (MHC-I), and genetic ablation of AXL in the experimental PyMT-induced 
tumor model was shown to induce MHC-I expression to even higher levels compared to IFN-γ-induced 
parental cells[126]. AXL inhibition enhances cytokine release and increases CD8+ T cell response in 
syngeneic models, resulting in an elevated cytotoxic T cell-dependent antitumor immune response after 
radiation, which could be further enhanced by ICB[126]. 
Carcinoma subclones with pronounced mesenchymal phenotypes emerging from sustained hypoxic stress 
of primary NSCLC cells in culture were shown to be less susceptible to NK and CTL cell-mediated lysis 
compared to subclones with a more epithelial phenotype[96]. This difference was associated with reduced 
expression of intercellular adhesion molecule 1 (ICAM1), UL16 binding protein 1 (ULBP1), and MHC-I 
as well as increased TGF-β expression in mesenchymal subclones[96]. It was shown that expression of 
AXL in the mesenchymal NSCLC clones was correlated with an increased cancer cell intrinsic resistance 
to immune cell-mediated killing by NK cells as well as autologous CTLs while AXL targeting via small 
molecule inhibition potently sensitized mesenchymal lung cancer cells to cytotoxic lymphocyte-mediated 
killing[127]. These findings raise the intriguing possibility that phenotypic plasticity may enable tumor cells to 
circumvent NK- and CTL-mediated cell killing. This has also been attributed to the associated cytoskeletal 
remodeling in tumor cells, interfering with immune synapse formation[96,128,129]. This process may provide a 
rationale to test EMP-targeting approaches to enhance antitumor immunotherapy[95,130,131]. 
The EMT-TF SNAI1 has been shown to have a strong impact on the cancer-immunity cycle. In human 
mammary carcinoma MCF7 cells, Akalay et al.[132] observed that overexpression of exogenous SNAI1 
correlated with increased mesenchymal and stemness traits in these cells while reducing their susceptibility 
to CTL-mediated lysis. This was in part explained by reduced MHC expression in the SNAI1-transfected 
MCF7 derivatives and concomitant reduced activity of TCR signaling at the site of cell-cell contact 
(immunological synapse). Similar observations were reported using another MCF-7 derivative displaying 
hyperactive TGF-β signaling. Likewise, SNAI1 overexpression in murine B16 melanoma cells resulted in 
inhibition of CTL lysis activity, inhibition of DC maturation and expansion of suppressive Treg-like CD4+ 
Foxp3+ cells in a mechanism involving thrombospondin (TSP1) and TGF-β secretion[130]. Using PyMT 
cells, a murine transplantable model of breast cancer carcinoma, Dongre and colleagues showed that 
tumors arising with a more mesenchymal phenotype and high expression of SNAI1 expressed more PD-L1 
and less MHC-I and had less cytotoxic T cells, but were enriched for immunosuppressive components 
including M2 macrophages and Tregs[133]. The link between EMP and the presence of immunosuppressive 
macrophages seems to be critical. Although the mechanisms are still unclear, it is tempting to speculate 
the involvement of immunosuppressive chemoattractants (e.g., TGF-β) in the recruitment of macrophages 
to the TIME. Another interesting observation made by Dongre and colleagues was that NK cells infiltrate 
mesenchymal tumors more effectively compared to the epithelial tumors, which can be explained by 
downregulation of MHC-I in the more mesenchymal tumors[133]. However, despite this NK enrichment, 
the mesenchymal tumors rapidly grow in this model suggesting intrinsic or extrinsic resistance as well as 
possible cooperative effects.
Converging preclinical evidence also suggests that tumors with a more EMP/mesenchymal phenotype 
are less responsive to ICB. SNAI1+ melanoma tumors were unresponsive to immunotherapy, but 
targeting SNAI1 with siRNA or anti-TSP1 monoclonal antibody could inhibit tumor progression and 
induce systemic immune responses[130]. In ZEB1/miR-200-driven NSCLC models as well as in SNAI1-
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driven breast cancer models, EMP was associated with PD-L1 expression[134]. Targeting PD-L1 in NSCLC 
efficiently prevented tumor growth and metastasis. In PyMT breast cancer models, epithelial tumors were 
susceptible to elimination by anti-CTLA-4 immunotherapy, whereas corresponding mesenchymal tumors 
were refractory to such treatment[133]. By injecting E/M cells at various ratios, these investigators also 
elegantly demonstrated that in the case of mixed epithelial-mesenchymal tumors, even the presence of 
rare mesenchymal carcinoma cells could protect the epithelial counterpart from anti-CTLA-4 treatment by 
promoting the recruitment of immunosuppressive cells including M2 macrophages and Tregs[133]. 
EMP as a mediator of primary and acquired ICB resistance 
Sharma and colleagues have described three different categories of resistance against immunotherapy: 
primary, adaptive and acquired resistance[37]. Primary, or innate, resistance to immunotherapy occurs when 
the cancer does not have an initial response (i.e., it is refractory) to the therapy. Adaptive resistance occurs 
when the tumor is initially recognized by the immune system, but the tumor adapts to escape immune 
attack. Given the evolving nature of the interaction between immune cells and cancer cells in this process, 
adaptive resistance can manifest clinically as either primary resistance, mixed responses or acquired 
resistance. Thus, only clinical data describing the role of EMP in primary and acquired resistance will be 
discussed here. Acquired resistance describes the clinical scenario in which the cancer initially responded 
to immunotherapy but recurs and progresses after a period of time. However, as Sharma and colleagues 
emphasize in their review, the immune response is dynamic and can evolve for each patient and tumor, 
and could also be affected by environmental and genetic factors as well as by the cancer treatment[37]. 
Accordingly, it is important to note that the process of immunoediting mentioned above is anything but 
a static process, as novel rounds of therapy and subsequent immunoediting affect the composition of the 
TIME through clonal selection acting on pre-existing cancer cell populations or de novo acquisition of 
resistant traits.
EMP in primary ICB resistance 
The hypothesis that epithelial phenotypic plasticity could be a key determinant of the outcome of 
immune checkpoint inhibition in cancer is fueled by pioneer transcriptional data[135]. Hugo and colleagues 
performed exome and transcriptomic sequencing of melanoma pre-treatment samples, and a common 
gene signature was shown to characterize tumors that were non-responsive to anti-PD-1 therapy[135]. 
This innate PD-1 resistance (IPRES) gene signature encapsulates the upregulation of EMT transcription 
factors, immunosuppressive cytokines, and pro-angiogenic factors[135]. The IPRES signature, enriched in 
non-responding patients, overlaps with signatures for wound-healing, angiogenesis, ECM remodeling, 
cell adhesion, monocyte/macrophage chemotaxis and resistance to MAPK pathway inhibition[135]. Data 
from The Cancer Genome Atlas (TCGA), PROSPECT, and BATTLE-1 showed that inflammatory changes 
in the tumor microenvironment were strongly associated with induction of EMT signatures in lung 
adenocarcinoma, which in turn correlated with upregulation of multiple suppressive immune checkpoint 
receptors or their ligands, including B7-H3, CTLA-4, PD-1, PD-L1, PD-L2, B and T lymphocyte attenuator, 
and T cell immunoglobulin and mucin-domain containing-3 (TIM-3)[45]. Taken together, these data suggest 
that attenuating the mechanics underlying the IPRES signature may have the potential to enhance anti-
PD-1 responses in melanoma and other cancers. Intriguingly, the receptor tyrosine kinase AXL, whose 
upregulation is associated with a reversible plasticity cell state[94] and is part of the “jackpot” signature 
of pre-existing pre-resistant cells[91], was found to be a component of the IPRES signature among 532 
upregulated genes including several EMT and EMP mediators such as EGFR, NGF, CDH11, EPHA3, HEY1, 
HEY (NOTCH effectors), TWIST2, ID3, ID1, many interleukins including immunosuppressive IL10, 
ITGA5/8; LOX, LOXL2, MMP1, MMP2, MMP3, MMP9, NRP1, THBS1 and THBS2, NUMBL (plasticity 
factor), ROR2, RORB, RUNX2, SEMA3A SERPINE1 VEGFA, VEGFC and Wnt genes WNT11 WNT2 
WNT5A WNT7B and DKK3. Among the 161 genes downregulated in the IPRES signature are HLA-A and 
E-cadherin (CDH1)[135].
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In line with these findings from melanoma, Thompson and colleagues recently observed that NSCLC 
tumors displaying a more mesenchymal phenotype showed reduced clinical responses to ICB[136]. In 
this study, an EMT/inflammation-based signature had clinical utility in predicting clinical response[136], 
supporting the view that the EMP signature is an adverse predictor of ICB response across tumor types.
Furthermore, in urothelial cancer patients with T cell-infiltrated tumors, a higher EMT/stroma-related 
gene expression signature was associated with poor response and disease progression under anti-PD-1 
therapy[137]. This study suggested that stromal elements are the major source of immune resistance in this 
setting, thus providing a rationale for co-targeting PD-1 and the stromal elements mediating resistance[137]. 
EMP in acquired resistance to ICB
Potential mechanisms of acquired resistance to immunotherapy include loss of T-cell function, 
downregulation of tumor-associated antigen presentation, and acquisition of mutations that enable immune 
escape[37]. The IFN-γ pathway plays an important regulatory role at the center stage of primary, adaptive 
and acquired resistance to ICB[37]. IFN-γ, which is secreted primarily by T cells and NK cells, is crucial to 
initiate an effective antitumor immune response as it mediates increased MHC-I expression, recruitment of 
immune cells and direct antiproliferative and pro-apoptotic effects in cancer cells[129]. However, constitutive 
IFN-γ exposure might initiate immunoediting and subsequent immune escape by promoting alteration of 
the molecules involved in IFN signaling pathways such as Janus kinase/signal transducers and activators 
of transcription (JAK/STAT) and induction of EMT[37]. For example, an increased frequency of IFN-γ 
pathway gene mutations in tumors of melanoma patients that did not respond to the anti-CTLA-4 antibody 
ipilimumab has been shown[37,138]. Mutations in the IFN-γ pathway could also result in lack of IFN-γ-
induced PD-L1 expression causing primary resistance to PD-1 blockade[37,139].
Cancer cell activation of the Wnt/β-catenin pathway or activation of the phosphoinositide 3-kinase (PI3K)/
AKT signaling pathway, through, e.g., acquired loss of the tumor suppressor protein phosphatase PTEN, 
have both been shown to regulate EMT, and both signaling pathways have been mechanistically linked 
to immune resistance in preclinical studies[140-144]. Trujillo and colleagues performed a molecular analysis 
of baseline and treatment-resistant tumor samples from two malignant melanoma patients who initially 
showed a durable partial response to either a melanoma-peptide/interleukin-12 vaccine or combined 
anti-CTLA-4 + anti-PD-1 therapy and subsequently developed new treatment-resistant metastases. 
Transcriptional profiling and genomic sequencing for oncogenic alterations as well as histologic analysis for 
T cell infiltration were performed to investigate mechanisms of acquired resistance to immunotherapy[144]. 
In the first case, the authors found increased tumor cell intrinsic activation of β-catenin in the patient’s 
treatment-resistant metastasis, whereas in the second case genomic sequencing revealed acquired biallelic 
PTEN loss, while both cases were associated with loss of T cell infiltration[144]. This study highlights that 
continued analysis of acquired resistance samples is crucial to identify potentially targetable resistance 
pathways amenable to therapeutic intervention.
Expression of IL8 by tumor cells has been shown to promote their EMP[108]. Thus, IL8 and its receptor 
CXCR1/2 axis have been established as potential EMP regulating factors and subsequent targeting of 
the IL8/CXCR1/2 axis has been explored as a promising EMP target. Preclinical studies have also been 
performed combining CXCR1/2 blockade with bifunctional anti-TGF-β RII/PD-L1[145]. In this study, Horn 
and colleagues were able to show that simultaneous inhibition of TGF-β, PD-L1 and CXCR1/2 in murine 
breast and lung cancers synergized to reverse EMP and associated mesenchymal features, reduce infiltration 
by immunosuppressive MDSCs, and enhance T cell infiltration and overall antitumor immune response[145].
Clinical trials: targeting EMP to improve immunotherapy of cancer
Combination therapies being tested that seek to enhance the immune response have been extensively 
reviewed elsewhere[49,146]. From the discussion above, it is evident that it is not clear which combination of 
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the multifaceted characteristics of EMP drives the prominent resistance to ICB, and thus it is also not clear 
how EMP may be targeted most effectively in various cancer contexts. The multiple pathways involved 
in the initiation and maintenance of epithelial plasticity and the redundancy between these overlapping 
pathways makes EMP a challenging target. Attempts are being made to target EMP through the multitude 
of soluble factors, receptors, and transcription factors involved. Several combinations with ICB have been 
explored in preclinical models, and a few trials have been initiated based on the hypothesis that EMP 
is one of the main mediators compromising the efficacy of ICB therapies and that targeting EMP could 
lead to stronger and more durable ICB responses [Table 1]. Here, we will specifically highlight promising 
therapeutic agents targeting EMP-mediated mechanisms of ICB resistance and discuss them in light of the 
available mechanistic data to support their multifaceted mechanism of action within the TIME.
TGF-β is a major regulator of the tumor microenvironment, and also a potent inducer of cancer cell EMT 
and immune suppression[61,86,97,98]. TGF-β is being explored as a target for combination with ICB. Recent 
retrospective and preclinical reports highlight its role in ICB resistance, while mechanistic and clinical 
studies continue to refine targeting strategies and synergy with checkpoint blockade. TGF-β is expressed 
in cancer, stromal and immune cells in three isoforms, TGF-β1, β2, and β3. Several pan-cancer gene 
expression analyses have shown that TGF-β1 is the primary isoform expressed in tumors, while TGF-β3 
is less frequently observed and TGF-β2 is rarely detected and mainly serves to regulate normal cardiac 
function and hematopoiesis, which helps explain the failure of earlier pan-TGF-β targeting therapies due 
to toxicity-related adverse events[108,147,148]. The most common proposed mechanisms of TGF-β-driven ICB 
resistance are CD8+ T cell exclusion via fibroblast differentiation and subsequent stromal remodeling 
and inhibition of CD4+ T helper cell differentiation to the immune-activating T-helper (Th)1 effector 
cell phenotype, as these conditions have been reproduced in various mouse tumor models and effectively 
treated by combined targeting of TGF-β and the PD-1/PD-L1 axis[149-152]. Additionally, anti-TGF-β was 
shown to act in synergy with ICB by suppressing immunosuppressive Tregs and EMT in cancer cells in a 
murine squamous cell carcinoma (SCC) model[153]. However, not all tumor models respond equally well to 
the combination since its efficacy seems to be highly dependent on CTL anti-tumor activity, suggesting that 
the most immunogenic tumors are expected to benefit the most from this combination[150]. 
Target Drug name Type Cancer type Latest phase* Clinical trial number**
TGF-βRI Vactosertib + 
durvalumab
Selective TKI Urothelial II NCT04064190









Sitravatinib Pan-TKI NSCLC III NCT03906071
ccRCC II NCT03680521
Urothelial II NCT03606174
c-MET/VEGFR2/AXL/RET Cabozantinib Pan-TKI RCC III NCT03937219
AXL Bemcentinib Selective TKI NSCLC II NCT03184571
Mesothelioma II NCT03654833
Breast cancer II NCT03184558
Melanoma II NCT02872259
Table 1. Clinical trials where EMP targets are being evaluated in combination with ICB targeting the PD-1/PD-L1 axis
*Only phase II or later trials are shown. Trials designated as phase I/II are listed as latest phase = II; **Trial identifiers and associated 
information obtained from www.clinicaltrials.gov. TKIs: tyrosine kinase inhibitors; NSCLC: non-small cell lung cancer; RCC: renal cell 
carcinoma; TGF-β: transforming growth factor-beta; PD-L1: programmed death-ligand 1
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TGF-β-targeting therapies in combination clinical trials with ICB for advanced solid cancers include the 
small molecule tyrosine kinase inhibitors (TKIs) vactosertib and LY3200882, which specifically target 
TGF-βRI signaling via ALK5 inhibition (NCT04158700, NCT04064190, NCT02937272)[108]. The most 
advanced of these, galunisertib, has been shown to inhibit in vivo cancer cell invasion and metastasis in 
addition to the mechanisms mentioned above[154]; however, it also inhibits p38α due to its similarity to 
ALK5, and this may contribute to potentially serious side effects that have caused other TKIs in this class 
of drugs to fail[155]. It was recently announced that Eli Lilly discontinued the development of galusertinib. 
However, several alternative TGF-β-targeting strategies are also being tested in the clinic, including 
AVID200, a novel fusion protein that specifically traps free TGF-β1/3 and has recently shown promising 
safety in a phase I monotherapy trial[148], and bintrafusp-alfa (formerly M7824), an anti-PD-L1/TGF-βRII 
fusion protein that functions both as a checkpoint inhibitor and a TIME-localized TGF-β trap. Bintrafusp 
alfa has shown superior efficacy in several murine models compared to anti-PD-L1 and anti-TGF-β 
administered both alone and in combination while also reversing TGF-β1-induced tumor cell plasticity[108], 
prompting multiple clinical trials in various malignancies including lung (NSCLC and SCLC), breast, 
cervical, and colorectal (CRC) cancers as monotherapy or in combination with radio- or chemotherapy 
(NCT02517398, NCT03554473, NCT03620201, NCT03524170, NCT03579472, NCT04246489, 
NCT03436563). Notable among these is the trial in second-line advanced NSCLC (unselected for PD-L1 
expression level), which has shown durable responses and encouraging long-term survival while 
maintaining a manageable safety profile over a two-year follow-up period, prompting a randomized phase 
III clinical trial vs. pembrolizumab in first-line PD-L1-high NSCLC (NCT03631706)[156].
AXL receptor tyrosine kinase (RTK) has been consistently linked to EMT-mediated drug resistance in 
a number of cancers[157], and thus represents a promising drug target in this context. AXL expression 
is prevalent in EMT- and stem cell-related gene expression profiles, highlighting its role in facilitating 
plasticity phenotypes[95,158-160]. AXL signaling has also been shown to contribute uniquely to both tumor 
intrinsic and microenvironmental immunosuppression and is initiated by its ligand Gas6 as well as 
heterodimerization with other RTKs. Antony and colleagues showed that GAS6-AXL signaling network 
is a mesenchymal molecular subtype-specific therapeutic target in ovarian cancer[161]. Of note, this paper 
also elegantly demonstrated the crucial role of AXL moving from cholesterol-rich lipid rafts in epithelial 
carcinoma cells to the normal plasma membrane domain where it multimerizes with other RTKs in 
mesenchymal carcinoma cells[161]. In a later study, Antony and co-authors were able to demonstrate that 
the tumor suppressor opioid-binding protein/cell adhesion molecule (OPCML), which is silenced in over 
83% of ovarian carcinomas by loss of heterozygosity or by epigenetic mechanisms, is spatially restricted to 
the cholesterol-rich lipid rafts together with AXL, and when present, represses AXL-dependent oncogenic 
signaling through protein tyrosine phosphatase receptor type G (PTPRG) in a coordinated manner[162]. 
This study also serves to illustrate how two spatially restricted tumor suppressors, OPCML and PTPRG, 
coordinate to repress AXL-dependent oncogenic signaling in the Epi context, and where the loss of lipid raft 
organization upon EMT could lead to overactivation of AXL and more promiscuous heterodimerization 
with other RTKs in the M state. Thus, a therapeutic strategy to re-introduce OPCML represents an 
opportunity to target signaling networks, as opposed to more linear systems[158]. AXL signaling activates 
downstream MAPK/ERK and PI3K/Akt pathways, which are known to drive cell survival, proliferation, 
migration and invasion, both of which are crucial for cancer progression and associated with poor patient 
outcomes[157,163]. AXL inhibition in malignant tumors holds the potential to target AXL-mediated epithelial 
plasticity, stimulate antigen presentation, and block the recruitment of immunosuppressive macrophages 
to the TIME[164,165]. As such, several AXL-targeting therapeutics have emerged and are in various 
phases of clinical development in combination with ICB[108]. Although not initially developed as AXL-
targeting agents, pan-TKIs that inhibit a spectrum of RTKs including AXL, most notably cabozantinib 
and sitravatinib, have shown promising activity in combination with ICB particularly in ICB-naïve 
renal cell carcinoma (NCT03937219, NCT03680521). The most advanced clinical stage selective small 
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molecule AXL kinase inhibitor is bemcentinib (BGB324, formerly R428)[159,166]. Bemcentinib is currently 
in phase II development for a variety of malignancies including NSCLC (NCT03184571), mesothelioma 
(NCT03654833), triple-negative breast cancer (NCT03184558), and melanoma (NCT02872259) in 
combination with pembrolizumab. A recent presentation of results from an ICB-naive, advanced NSCLC 
cohort treated with bemcentinib and pembrolizumab (NCT03184571) reported improved overall 
response and disease control rates with a promising safety profile compared to previous benchmarks 
of pembrolizumab monotherapy and salvage chemotherapy. Strikingly, transcriptional analysis showed 
that pretreatment tumor biopsy samples from patients who turned out to be durable responders to the 
combination treatment displayed significant upregulation of EMT and myeloid activation gene expression 
signatures including AXL and TGFB1. In contrast, a negative regulation of EMT gene signature was 
downregulated; notably, PD-L1 and INFG levels were not associated with response. Importantly, over half 
the patients in the cohort were also PD-L1 negative (< 1% tumor positive cells) as assessed by IHC staining 
of pretreatment biopsies, although the particular assay does not account for PD-L1 expression in immune 
cells which may play a significant role[167]. By the same token, stratification of patients based on AXL IHC 
staining of both tumor and immune cells was associated with significantly improved patient survival[168]. 
In addition to enhancing responses to non-inflamed (PD-L1-low) tumors, EMT targeting is currently 
being pursued as a strategy to restore the efficacy of ICB by rechallenging ICB-refractory patients with 
EMT-ICB combination therapies. In NSCLC, ICB-refractory patients are increasingly treated with salvage 
chemotherapy, as prior ICB regimens appear to have a chemo-sensitization effect[169]. However, reversing 
the acquired ICB resistance may have an even more desirable effect. Phase II ICB combination trials of 
both bemcentinib (NCT03184571) and sitravatinib (NCT02954991) in ICB-refractory NSCLC have shown 
promising results compared to salvage chemotherapy benchmarks, and have allowed the advancement of 
sitravatinib to a phase III randomized trial vs. docetaxel (NCT03906071) and also to a phase II trial in ICB-
refractory urothelial carcinoma (NCT03606174).
Members of the TAM family of RTKs (TYRO3, AXL and MER) have emerged as attractive targets 
for cancer therapy, and they have received a great deal of attention for ICB combination due to their 
suppressive functions in innate immune cells[19,170]. Thus, TAM receptor inhibition is expected to unleash 
an innate-driven antitumor immune response; however, blocking all three family members is expected to 
yield intolerable side-effects. Thus, specific inhibitors targeting one family member only are most advanced 
in clinical testing. Selectively targeting only MERTK is also expected to have ambiguous effects; in addition 
to expression on a myriad innate immune cells MERTK has also emerged as a T-cell costimulatory 
molecule[170]. Thus, targeting MERTK in the TIME is expected to negatively affect T cell functionality, 
rendering PD-1 therapy counter-productive[170]. Targeting the other family members AXL or TYRO3 
with specific inhibitors is expected to yield a primarily antitumor immunological effect as these receptors 
predominantly function as immune-inhibitory receptors on APCs. 
Accordingly, it is important to stress that targeting a given pathway may affect several of the innate or 
acquired resistance mechanisms mentioned in the previous sections due to the concerted upregulation of 
the pathway in multiple compartments of the TIME and the diverse yet coordinated functions that this 
conserved biological program engages; thus, the observed effect when combining targeted therapies with 
ICB in a given patient population may also be driven by one or more uncharacterized mechanisms of 
action. Using AXL targeting as an example, apart from its expression on subpopulations of mesenchymal 
cancer cells, AXL is also present on a number of immune cell types, particularly myeloid-derived suppressor 
cells and M2 polarized macrophages, where it confers an immunosuppressive role in tumor and normal 
inflammatory environments[163,170]. AXL expressing DCs were shown to display phenotypic and functional 
diversity, and this population of cells was suggested to represent in situ plasticity of the plasmacytoid 
dendritic cell lineage[171]. Recently, an AXL+ regulatory DC population that strongly suppresses antitumor 
immunity was characterized[172]. AXL is a well-established negative-feedback regulator of the innate 
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immune response by dampening the TLR response[173], and as AXL inhibition has been shown to elicit an 
immunogenic form of cell death in cancer cells, it is expected to initiate a strong innate anticancer immune 
response through recruitment and activation of APCs[53,124,170]. Furthermore, inhibiting AXL has significant 
anti-angiogenic potential which may normalize the tumor vasculature, reduce hypoxia and play a role in 
reversing ICB resistance[146]; not only does AXL signaling blockade in tumor cells decrease secretion of pro-
angiogenic factors, but it also directly impairs vascular endothelial growth factor A-dependent angiogenesis 
in vessel endothelial cells, which ubiquitously express AXL[165]. 
CONCLUSION
From in vitro models and preclinical in vivo models, targeting EMP has emerged as one of the most 
promising strategies to increase both the response rates and duration of responses to ICB. Since most novel 
EMP-targeting drugs are currently in early phases of clinical development, it follows that these therapies 
must first be tested on patients who have failed currently approved standard-of-care treatments, which in 
many cases include ICB. Reversal, rather than prevention, of EMP is therefore being tested in most current 
clinical trials [Table 1], although for most compounds, the optimal strategy would be to move from second-
line combination testing to 1st line combination with ICB. In the long term, based on preclinical evidence 
that EMP targeting might also enhance natural cancer immunosurveillance in a cancer preventive setting, 
it would be of great interest to also evaluate the efficacy of several drug candidates mentioned above in 
Table 1 in chemoprevention. In the chemopreventive context specifically, it will be important to monitor 
potentially toxic long-term effects, as the targeted pathways are expected to also affect both the immune 
and stem/progenitor cell populations necessary for maintaining physiological homeostasis and repair 
processes[78]. 
Most of the genomic studies thus far have relied solely on analyses of pretreatment samples, and thus the 
results obtained provide a brief snapshot that may be useful to dissect the hallmarks of innate resistance vs. 
response, whereas longitudinal sampling would provide deeper insight into the cellular heterogeneity and 
dynamics of acquired therapy resistance and associated intercellular communication. This information is 
crucial to determine which targets of EMP modulators induce optimal antitumor responses in combination 
with ICB in a particular context. The sum of the alterations induced in the variety of cellular populations 
in the TIME eventually constitutes the clinical benefit of these combination regimens. Several clinical 
scenarios as explained above could benefit from a rational combination strategy including EMP inhibitors 
[Table 1], and biomarker- or biosignature-driven clinical trial design is also expected to contribute more 
effectively to our biological understanding. Clearly, targeting EMP impacts the dynamic and fine-tuned 
regulation of the myriad cellular compartments differently. Although not covered in depth in this review, 
phenotypic and functional plasticity of immune cells are also expected to be affected by interventions 
targeting cancer EMP and contribute to clinical benefit. Much is yet to be learned regarding how EMP 
targeting might shift the polarization of immune cell phenotypes in a manner that either supports or 
represses antitumor immunity. High-dimensional single cell technologies are expected to shed light on 
these important questions regarding the spatial and temporal regulation of EMP in the TIME. The complex 
intercellular communication within the TIME, although much remains unknown, holds significant 
promise; increased knowledge regarding this intricate interplay may enable the coordinated polarization of 
cancer and immune cells in the TIME to be effectively targeted through EMP in a tailored and therapeutic 
fashion to improve the efficacy of cancer ICB combination therapies.
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